Vitaflo Australia

44 PBAC submissions on file, active 2014–2024. 89% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Amino acid formula with vitamins and minerals (multiple formulations)
  Metabolic · Recommended with restriction · 2021—
• Amino acid formula with vitamins and minerals without phenylalanine
  Metabolic · Recommended · 2024other sponsor
• Amino acid formula with vitamins and minerals without lysine and low in tryptophan
  Metabolic · Recommended · 2024—
• Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
  Metabolic · Recommended with restriction · 2020other sponsor
• Glycomacropeptide and essential amino acids with vitamins and minerals
  Metabolic · Recommended · 2024other sponsor
• Protein formula with vitamins and minerals, low in potassium, phosphorus, calcium, chloride and vitamin a
  Metabolic · Recommended with restriction · 2020—
• Triglycerides medium chain formula
  Metabolic · Recommended with restriction · 2020other sponsor
• Triglycerides, long chain with glucose polymer
  Metabolic · Recommended with restriction · 2024—
• Vitamins, minerals and trace elements with carbohydrate
  Metabolic · Recommended with restriction · 2020other sponsor
• Amino acid formula with vitamins and minerals (msud, tyr, hcu coolers)
  Metabolic · Recommended · 2018—
• Amino acid formula with vitamins and minerals without methionine and supplemented with arachidonic acid and docosahexaenoic acid
  Metabolic · Recommended with restriction · 2023—
• Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine
  Metabolic · Recommended · 2024—
• Amino acid formula with vitamins and minerals without phenylalanine and tyrosine
  Metabolic · Recommended with restriction · 2020other sponsor
• Amino acid formula with vitamins and minerals without valine, leucine, isoleucine, supplemented with arachidonic acid and docosahexaenoic acid
  Metabolic · Recommended · 2023—
• Amino acid formula with vitamins and minerals, low phenylalanine and supplemented with docosahexaenoic acid and arachidonic acid
  Metabolic · Recommended · 2019—
• Amino acid formula with vitamins and minerals, without phenylalanine and tyrosine, supplemented with arachidonic acid and docosahexaenoic acid
  Metabolic · Recommended · 2023—
• Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids, without phenylalanine
  Metabolic · Recommended with restriction · 2018—
• Carbohydrate formula with minerals
  Metabolic · Not recommended · 2016—
• Essential amino acids formula with vitamins and minerals
  Metabolic · Recommended · 2021—
• Glycine with carbohydrate
  Metabolic · Recommended with restriction · 2014—
• Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine
  Metabolic · Recommended · 2022—
• Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low phenylalanine
  Metabolic · Recommended · 2017—
• High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate
  Metabolic · Recommended · 2023other sponsor
• High fat formula with vitamins, minerals and trace elements and low in protein carbohydrate
  Metabolic · Recommended with restriction · 2016—
• Triglycerides, long chain; triglycerides, medium chain
  Metabolic · Recommended · 2017—
• Triglycerides, medium chain
  Metabolic · Recommended · 2022—
• Triglycerides, medium chain; triglycerides, long chain
  Metabolic · Not recommended · 2017—
• Tyrosine with carbohydrate
  Metabolic · Recommended with restriction · 2019—
• Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, low in protein, phosphate, potassium and lactose
  Other · Recommended with restriction · 2020—

Therapy area mix

Activity by year

2014 (4) · 2015 (1) · 2016 (4) · 2017 (6) · 2018 (4) · 2019 (5) · 2020 (4) · 2021 (7) · 2022 (3) · 2023 (3) · 2024 (3)

Rejection patterns

Across 4 Not recommended decisions on file.

• 1×High risk of product wastage due to short shelf life and sporadic patient use
• 1×lack of clarity surrounding the indications leading to risk of use outside restrictions
• 1×inappropriate comparator (ProZero® contains fats while SOS® products do not)
• 1×lack of clinical data supporting the new indication of proven inborn errors of fat metabolism
• 1×Increase in maximum quantity per script not clinically appropriate